Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
about
Guarding the 'translation apparatus': defective ribosome biogenesis and the p53 signaling pathwayEstablished and emerging targeted therapies in the myelodysplastic syndromes.The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-AnalysisWHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).Current therapy of myelodysplastic syndromesTransformation of the 5q- syndrome to acute lymphoblastic leukemia: a report of two cases and review of the literatureClinical utility of lenalidomide in the treatment of myelodysplastic syndromesTreatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.Pharmacotherapy of myelodysplastic syndromes.Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.Update on cytogenetic and molecular changes in myelodysplastic syndromes.Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesMyelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.Update on the pharmacotherapy for myelodysplastic syndromes.Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia.Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A.Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.Guidelines for the diagnosis and management of adult myelodysplastic syndromes.Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients.
P2860
Q27022918-280D0FBB-8A50-4D8D-941E-8B5384C748B2Q30245476-53F581B2-DD6E-4D9E-B30F-903AA290FFDDQ33398044-74B48A93-04E1-45A8-B895-BA4AC095147EQ33408873-21D817C8-DBAD-4812-A749-CE252DD35313Q33424228-559A94F1-13E1-4A2E-AD1E-667B8BFDF05AQ33436627-40F8A70A-A828-4CE5-BE37-5BF162036784Q33581974-57EDD085-F3AC-4012-B00F-2EE2FC978EEDQ33695954-297634F8-4F62-4364-836B-87EB7F050809Q34013796-9A319CF2-12F6-4F25-8D24-C37ACB1FBD1BQ34766950-0F36E109-D5F5-49CF-9AB5-C4EE29ECBB46Q34783754-7ED512B1-60EE-4152-ADAD-B71FC819DFE1Q35717799-C1F2F7CF-19F7-4445-825C-48DD633DB433Q36612675-9D1A2405-BBFC-4BB8-B3B0-27620AA25AE0Q36832931-7B6707B0-550F-4EAA-AA72-BAA8393B4230Q37441528-FADBF5AE-B5BD-4FC4-A7CD-C23A33552EFEQ37756975-FD77A714-232D-4E0B-B320-5EFF0B8C8A06Q37799831-F51B4F68-C32A-4B0D-92E1-1CF22F1D64CCQ37923939-AB74BD20-86C1-4123-B6E2-72693F1B34D4Q38074249-2C347F41-7438-4498-9AC7-0DC936FC6AA0Q38135713-666B22E5-F07D-4F1C-AD10-BD81BDB4399EQ38195796-E31EC4AB-0695-4578-B4CF-3C0DEF9FFB18Q38235662-B45D06D5-DC7D-4EDB-AAE5-1F045F4C1A86Q38352241-CBE64C37-F127-4543-ADB0-753A3A1E89BAQ38415206-26627E2A-D444-4442-8F76-841F75BAEEE9Q41156034-495BFE85-69AA-4A97-B6BA-ACD5C71A99BAQ41854078-7D0AC667-1C15-462B-B890-1BF99E5EF30CQ42586752-6B4ABB06-B4CB-4EE9-927F-99BCE562A4E7Q42879201-933744FC-E384-4675-B170-71CDA6CBCDCBQ43480924-3D647485-B82A-4ADD-9714-7180FCD2FB17Q50519753-1A7BE634-9FC5-41B8-9868-A9D1DB069817Q54392826-C6371E58-ABF0-448C-A005-C645838F2F12Q54594035-A4619786-32E8-49BD-B23F-3960C301954D
P2860
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Patients with del
@nl
Patients with del(5q) MDS who ...... evolution and AML progression.
@en
type
label
Patients with del
@nl
Patients with del(5q) MDS who ...... evolution and AML progression.
@en
prefLabel
Patients with del
@nl
Patients with del(5q) MDS who ...... evolution and AML progression.
@en
P2093
P1433
P1476
Patients with del(5q) MDS who ...... evolution and AML progression.
@en
P2093
Brigitte Schlegelberger
Eva Hellström-Lindberg
Gudrun Göhring
Guntram Büsche
Hans Heinrich Kreipe
Martin Zimmermann
P304
P356
10.1007/S00277-009-0846-Z
P577
2009-10-24T00:00:00Z